Central action of ketotifen

Area of Science:

• Neuropharmacology
• Behavioral Neuroscience
• Drug Discovery

Background:

• Ketotifen is a compound with a complex chemical structure.
• Understanding its neuropharmacological effects is crucial for potential therapeutic applications.
• Previous research has not fully elucidated its impact on motor activity and neurotransmitter systems.

Purpose of the Study:

• To investigate the effects of ketotifen on locomotor activity in rodent models.
• To explore ketotifen's potential interactions with serotonin and other neurotransmitter systems.
• To assess ketotifen's pharmacological profile, including antidepressant and cholinolytic properties.

Main Methods:

• Administration of ketotifen to mice and rats.
• Assessment of spontaneous and drug-induced locomotor activity (amphetamine, L-DOPA).
• Evaluation of hypothermia, reserpine-induced hypothermia, and various serotonin-related behavioral responses (head twitch, clonic convulsions, fenfluramine hyperthermia).
• Testing for effects on catalepsy and cholinolytic activity.
• Determination of median lethal dose (LD50).

Main Results:

• Ketotifen significantly inhibited spontaneous locomotor activity and amphetamine-induced hypermotility in mice and rats.
• It also reduced L-DOPA-induced motor stimulation in mice.
• Ketotifen exhibited serotoninolytic features, including inhibition of head twitches and antagonism of fenfluramine-induced hyperthermia, but lacked tricyclic antidepressant or cholinolytic effects.
• The median lethal dose (LD50) was determined to be 122.5 mg/kg in mice and 62.6 mg/kg in rats via intraperitoneal injection.

Conclusions:

• Ketotifen possesses significant motor-inhibiting properties and interacts with the serotonin system.
• Its pharmacological profile suggests it is not a tricyclic antidepressant and lacks cholinolytic activity.
• These findings provide insights into ketotifen's neurochemical actions and potential applications.